An Open-Label, Multicenter, Phase III Trial of ABI-007 vs Dacarbazine in Previously Untreated Patients With Metastatic Malignant Melanoma.
Phase of Trial: Phase III
Latest Information Update: 28 Apr 2017
At a glance
- Drugs Paclitaxel (Primary) ; Dacarbazine
- Indications Malignant melanoma
- Focus Biomarker; Pharmacogenomic; Registrational; Therapeutic Use
- Sponsors Celgene Corporation
- 07 Jun 2017 Biomarkers information updated
- 26 Sep 2015 Results published in the Annals of Oncology.
- 25 Jun 2014 According to the ClinicalTrials.gov record, status changed from active, no longer recruiting to completed.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History